Abera Bioscience (ABERA) Q3 2024 earnings summary

Executive summary

• Abera Bioscience focuses on developing mucosal vaccines using its patented BERA platform, targeting diseases like pneumococcus, influenza, and chlamydia, with a strategy to license candidates early in clinical development.

• The company secured significant grants from CEPI and Vinnova, and started preclinical studies for a nasal influenza vaccine, expanding its pipeline and validating its technology.

• Abera's universal pneumococcal vaccine, Ab-01.12, is designed for broad protection and cost-effective production, with all regulatory preclinical studies completed and clinical trials planned in collaboration with Radboud UMC.

Financial highlights

• Q3 2024 revenue was 3,348 KSEK, up from 0 KSEK in Q3 2023, mainly from grants and currency gains.

• Net loss for Q3 2024 was -278 KSEK, a significant improvement from -4,186 KSEK in Q3 2023, reflecting grant coverage of operating costs.

• Cash and bank balances at September 30, 2024, were 3,105 KSEK, up from 1,878 KSEK a year earlier.

• Cash flow from operations in Q3 2024 was 435 KSEK, compared to -3,324 KSEK in Q3 2023.

• Equity at period end was 8,524 KSEK, up from 8,083 KSEK at September 2023.

Outlook and guidance

• The company will not initiate GMP manufacturing or Phase 1 trials for Ab-01.12 until full financing is secured.

• Ongoing grants from UK Vaccine Network and CEPI provide funding through 2025, with payments tied to project milestones.

• Management is actively seeking additional funding and partnerships to support clinical development.